These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 37266989)
41. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. De Matteis E; Guglielmetti M; Ornello R; Spuntarelli V; Martelletti P; Sacco S Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430 [TBL] [Abstract][Full Text] [Related]
42. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials. Yang CP; Zeng BY; Chang CM; Shih PH; Yang CC; Tseng PT; Wang SJ Neurotherapeutics; 2021 Oct; 18(4):2639-2650. PubMed ID: 34580838 [TBL] [Abstract][Full Text] [Related]
43. Preventive pharmacologic treatments for episodic migraine in adults. Shamliyan TA; Choi JY; Ramakrishnan R; Miller JB; Wang SY; Taylor FR; Kane RL J Gen Intern Med; 2013 Sep; 28(9):1225-37. PubMed ID: 23592242 [TBL] [Abstract][Full Text] [Related]
44. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. Drellia K; Kokoti L; Deligianni CI; Papadopoulos D; Mitsikostas DD Cephalalgia; 2021 Jun; 41(7):851-864. PubMed ID: 33567891 [TBL] [Abstract][Full Text] [Related]
46. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies. Ailani J; Pearlman E; Zhang Q; Nagy AJ; Schuh K; Aurora SK Eur J Neurol; 2020 Mar; 27(3):542-549. PubMed ID: 31595600 [TBL] [Abstract][Full Text] [Related]
47. A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache. Jackson JL; Cogbill E; Santana-Davila R; Eldredge C; Collier W; Gradall A; Sehgal N; Kuester J PLoS One; 2015; 10(7):e0130733. PubMed ID: 26172390 [TBL] [Abstract][Full Text] [Related]
48. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients. Curone M; Tullo V; Didier HA; Bussone G Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032 [TBL] [Abstract][Full Text] [Related]
49. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today? Nagaraj K; Vandenbussche N; Goadsby PJ Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149 [TBL] [Abstract][Full Text] [Related]
50. Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis. Alasad YW; Asha MZ Clin Neurol Neurosurg; 2020 Aug; 195():105900. PubMed ID: 32460120 [TBL] [Abstract][Full Text] [Related]
51. Canadian Headache Society guideline for migraine prophylaxis. Pringsheim T; Davenport W; Mackie G; Worthington I; Aubé M; Christie SN; Gladstone J; Becker WJ; Can J Neurol Sci; 2012 Mar; 39(2 Suppl 2):S1-59. PubMed ID: 22683887 [TBL] [Abstract][Full Text] [Related]
52. Erenumab (Aimovig) for Migraine Prophylaxis in Adults. Shreiber AM Am Fam Physician; 2019 Jun; 99(12):781-782. PubMed ID: 31194488 [No Abstract] [Full Text] [Related]
53. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Reuter U; Ehrlich M; Gendolla A; Heinze A; Klatt J; Wen S; Hours-Zesiger P; Nickisch J; Sieder C; Hentschke C; Maier-Peuschel M Cephalalgia; 2022 Feb; 42(2):108-118. PubMed ID: 34743579 [TBL] [Abstract][Full Text] [Related]
54. Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine: an adjusted indirect treatment comparison. Briceño-Casado MDP; Gil-Sierra MD; Fénix-Caballero S Farm Hosp; 2020 Aug; 44(5):212-217. PubMed ID: 32853126 [TBL] [Abstract][Full Text] [Related]
55. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis. Soni P; Chawla E Clin Neurol Neurosurg; 2021 Oct; 209():106893. PubMed ID: 34464833 [TBL] [Abstract][Full Text] [Related]
57. CGRP Antibodies as Prophylaxis in Migraine. Edvinsson L Cell; 2018 Dec; 175(7):1719. PubMed ID: 30550780 [TBL] [Abstract][Full Text] [Related]
58. Drugs for hypertension. Med Lett Drugs Ther; 2020 May; 62(1598):73-80. PubMed ID: 32555118 [No Abstract] [Full Text] [Related]